2023 IASLC North America Conference on Lung Cancer Satellite Symposia
PER's Breast Cancer Symposia in San Antonio
Leukemia Therapy – A Look Into the Future
2023 Friday Satellite Symposia: Preceding the 65th ASH Annual Meeting and Exposition
Reflective Case-Based Oncology Collective: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
Burst CME™ - Part II – Advent of HER3 Targeted Approaches and Rationale in NSCLC Care
Burst CME™ - Part I – Overview of Pathophysiology, Diagnosis, and Management of HER3 Expressing Cancers
Burst CME™ - Part III – Advent of HER3 Targeted Approaches and Rationale in Breast Cancer Care
Administration of fam-trastuzumab deruxtecan significantly prolonged time-to-next treatment in patients with HER2-positive or HER2-low metastatic breast cancer, including patients who experienced changes in HER2 status during the treatment course.
The combination of nivolumab and ipilimumab led to a statistically significant and clinically meaningful improvement in progression-free survival per blinded independent central review compared with investigator’s choice of chemotherapy as frontline therapy in patients with metastatic colorectal cancer.
The Department of Immunology and Immunotherapy and the Icahn Genomics Institute at the Icahn School of Medicine at Mount Sinai have been awarded a $5 million grant from the National Cancer Institute of the National Institutes of Health to establish a state-of-the-art center dedicated to the discovery and development of cutting-edge targets for cancer therapy.
Tovorafenib elicited rapid, clinically meaningful tumor responses in pediatric patients with low-grade gliomas, including those with optic pathway gliomas, regardless of prior MAPK inhibitor status.
Precise stratification of hormone receptor–positive, HER2-negative breast cancer using BluePrint and MammaPrint assays revealed comparable 3-year recurrence-free survival rates between Black and White patients despite observed racial differences in the distribution of molecular subtypes.
The addition of tucatinib to ado-trastuzumab emtansine (T-DM1) significantly improved progression-free survival vs placebo plus T-DM1 in patients with previously treated HER2-positive metastatic breast cancer, including those with brain metastases.
Pembrolizumab plus olaparib did not improve progression-free or overall survival vs pembrolizumab plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer who received induction pembrolizumab plus chemotherapy.
The phase 2 BBI-20231001 trial evaluating the Boltbody immune-stimulating antibody conjugate BDC-1001 with or without pertuzumab in patients with HER2-positive breast adenocarcinoma is open for enrollment in the United States, France, Italy, and Spain.
The addition of pembrolizumab to neoadjuvant chemotherapy followed by adjuvant pembrolizumab plus endocrine therapy improved pathologic complete responses in key subsets of patients with early-stage, high-risk, estrogen receptor–positive/HER2-negative breast cancer enrolled in the phase 3 KEYNOTE-756 trial.
Detection of circulating tumor DNA with the Signatera assay was associated with disease recurrence in patients with hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer at 24 months post-randomization to treatment with adjuvant abemaciclib and endocrine therapy.
Capivasertib plus fulvestrant did not negatively affect quality of life compared with placebo plus fulvestrant in patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer.
Utilizing an artificial intelligence–assisted workflow to detect sentinel lymph node metastases in patients with breast cancer was deemed safe according to current diagnostic standards and reduced the need for immunohistochemistry and its associated financial burden.
The combination of ribociclib and endocrine therapy led to an improvement in progression-free survival and overall survival vs placebo plus endocrine therapy in patients with hormone receptor-positive/HER2-negative advanced breast cancer across all age groups.
The FDA has granted priority review to the supplemental biologics license application seeking the conversion of the accelerated approval of mirvetuximab soravtansine-gynx in patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who previously received 1 to 3 lines of systemic treatment to full approval.
The FDA has granted priority review to a supplemental biologics license application seeking the approval of nivolumab plus cisplatin-based chemotherapy as a frontline treatment option for adult patients with unresectable or metastatic urothelial carcinoma.
David Harpole, MD, discusses key data from the first interim analysis of the AEGEAN trial, changes to the adjuvant treatment landscape that inspired the subgroup analysis of patients with EGFR mutations excluded from the intention-to-treat population, and more.
A best practice clinical program developed by Florida Cancer Specialists & Research Institute, LLC is ensuring that patients with certain blood disorders achieve maximum clinical benefits from the use of oral medications.
The addition of serplulimab to carboplatin and nab-paclitaxel significantly prolonged survival vs chemotherapy alone when used in the first-line treatment of patients with previously untreated locally advanced or metastatic squamous non–small cell lung cancer.
Patients with non–small cell lung cancer harboring acquired EGFR mutations, such as C797S and intrinsic mutations in EGFR represent underserved populations where additional targeted therapies are needed.